跳转至内容
Merck
CN

SRP5030

FGFR2 (285-end), active, GST tagged human

PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥80% (SDS-PAGE), buffered aqueous glycerol solution

别名:

BFR-1, CD332, CEK3, ECT1, JWS, K-SAM, TK14, TK25

登录 查看组织和合同定价。

选择尺寸


关于此项目

NACRES:
NA.32
UNSPSC Code:
51111800
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

FGFR2 (285-end), active, GST tagged human, PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥80% (SDS-PAGE), buffered aqueous glycerol solution

recombinant

expressed in baculovirus infected Sf9 cells

product line

PRECISIO® Kinase

assay

≥80% (SDS-PAGE)

form

buffered aqueous glycerol solution

specific activity

100-136 nmol/min·mg

mol wt

~72 kDa

NCBI accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... FGFR2(2263)

General description

FGFR2 is a member of the fibroblast growth factor receptor family which play a role in mitogenesis and differentiation. FGFR2 is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, and mutations in FGFR2 are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. FGFR2 is required for early postimplantation development between implantation and the formation of the egg cylinder. FGFR2 contributes to the outgrowth, differentiation, and maintenance of the inner cell mass.

Physical form

Supplied in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

Preparation Note

after opening, aliquot into smaller quantities and store at -70 °C. Avoid repeating handling and multiple freeze/thaw cycles

Legal Information

PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Shih-hsin Kan et al.
American journal of human genetics, 70(2), 472-486 (2002-01-10)
It has been known for several years that heterozygous mutations of three members of the fibroblast growth-factor-receptor family of signal-transduction molecules-namely, FGFR1, FGFR2, and FGFR3-contribute significantly to disorders of bone patterning and growth. FGFR3 mutations, which predominantly cause short-limbed bone
E Arman et al.
Proceedings of the National Academy of Sciences of the United States of America, 95(9), 5082-5087 (1998-06-06)
We disrupted the fibroblast growth factor (FGF) receptor 2 (FGFR2) gene by introducing a neo cassette into the IIIc ligand binding exon and by deleting a genomic DNA fragment encoding its transmembrane domain and part of its kinase I domain.

相关内容

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持